ETFs Moderna, Inc.

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-24 pm EST			After market 04:22:55 pm
41.41 ^USD	-2.31%		41.54	+0.30%

09:27am	Sector Update: Health Care Stocks Decline Premarket Friday	MT
08:06am	Moderna to Supply COVID-19 Vaccines in EU, Norway	MT

ETFs positioned on Moderna, Inc.

Name	Weight	AuM	1st Jan change	Investor Rating
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	5.66%	0 M€	0.00%	-
BMO MSCI GENOMIC INNOVATION INDEX ETF - CAD	4.69%	0 M€	-.--%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	4.08%	0 M€	0.00%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.50%	1 M€	0.00%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	2.40%	30 M€	+2.82%	-
BMO MSCI INNOVATION INDEX ETF - CAD	2.08%	0 M€	-.--%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.81%	7 M€	0.00%
BAD ETF - USD	1.36%	0 M€	-4.31%	-
STRATEGY SHARES HALT CLIMATE CHANGE ETF - USD	1.21%	0 M€	+2.21%	-
DIREXION NASDAQ-100 EQUAL WEIGHTED ETF - USD	0.90%	1,239 M€	+5.17%
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	0.81%	1 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	0.72%	3 M€	-.--%
LEVERAGE SHARES PUBLIC LIMITED COMPANY - 3X LONG US TECH 100 ETP	0.63%	1 M€	-.--%	-
LEVERAGE SHARES -5X SHORT NASDAQ 100 ETP - USD	0.63%	5 M€	-14.64%	-
ARMOR US EQUITY INDEX ETF - USD	0.60%	0 M€	-.--%	-
ADVOCATE RISING RATE HEDGE ETF - USD	0.55%	0 M€	-72.95%	-
LEVERAGE SHARES 5X LONG NASDAQ 100 ETP - USD	0.45%	29 M€	0.00%	-
CSIF (IE) MSCI USA TECH 125 ESG UNIVERSAL BLUE UCITS ETF B - USD	0.34%	0 M€	-.--%
NOMURA NEXT FUNDS NASDAQ-100 ETF - JPY	0.22%	496 M€	+0.15%	-
SYNTAX STRATIFIED TOTAL MARKET II ETF - USD	0.21%	0 M€	+12.96%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET ETF - USD	0.21%	0 M€	+12.98%	-

1 2 3 4

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (97.4%); - grant revenue (1.4%); - revenue from collaboration agreements (1.2%). At the end of 2023, the group possessed a portfolio of 41 products in clinical development, of which 6 in phase III, 12 in phase II and 18 in phase I, and 5 products in preclinical development. Net sales are distributed geographically as follows: the United States (27.7%), Europe (19.8%) and other (52.5%).

Employees

5,600

Sector

Biotechnology & Medical Research

Calendar

2025-02-13 - Q4 2024 Earnings Call

More about the company